Financial Data and Key Metrics Changes - IRadimed achieved record revenue for the 18th consecutive quarter, with Q4 2025 revenue reaching $22.7 million, a 17% increase from Q4 2024, and full-year revenue of $83.8 million, up 14% year-over-year [3][10] - GAAP Diluted Earnings Per Share for Q4 was $0.50, up 25%, while non-GAAP Diluted Earnings Per Share was $0.54, up 23% [3][12] - Gross margins remained strong at approximately 77% for the year and 75% for Q4 [3][11] Business Line Data and Key Metrics Changes - MRI-compatible infusion pump systems contributed $9.1 million, up 20% year-over-year, while patient vital signs monitoring systems contributed $7.1 million, up 7.5% [10] - Disposable revenue grew 18% to $4.3 million, reflecting increased utilization of devices [10][11] - Ferromagnetic detection systems also saw solid gains, contributing to overall revenue growth [10] Market Data and Key Metrics Changes - Domestic sales accounted for 81% of total revenue in Q4 and 84% for the full year, indicating strong U.S. market performance [11] - There are approximately 6,400 5+-year-old 3860/3861 pump channels in the U.S. market that are up for replacement, with a target of adding an additional 1,000 channels per year through replacement sales [5][6] Company Strategy and Development Direction - The company anticipates a significant increase in revenue from the large replacement opportunity, which is expected to be a key growth driver for the next several years [5][7] - The new 3870 MR IV pump is expected to penetrate greenfield opportunities more effectively and increase utilization among existing customers [4][5] - The company plans to maintain quarterly revenue in the first half of 2026, driven by growth in MRI monitoring and the 3860 pump backlog, with significant bookings expected for the 3870 systems [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a $100 million-plus revenue run rate during 2026, driven by the new 3870 pump and other product lines [7] - The initial market feedback for the 3870 pump has been very positive, with excitement from users regarding its modernized design and functionality [16][18] - The company is working on regulatory approvals for the 3870 in Europe and Japan, with expectations for CE mark by the end of 2026 and clearance in Japan by summer 2027 [33] Other Important Information - Cash and cash equivalents at year-end were $51.2 million, with cash flow from operations of $5.9 million for Q4 and $24.9 million for the full year [12] - The company is managing inventory levels closely during the transition from the 3860 to the 3870 pump [30] Q&A Session Summary Question: Initial market feedback from the pilot for the 3870 pump - Management reported very positive feedback from initial users, with additional orders already on the books [15][16] Question: Gross margin scaling expectations - Management anticipates gross margins to remain in line initially but expects improvement in the second half of the year as production ramps up [19][20] Question: Future R&D efforts post-3870 launch - The R&D team is already working on a next-generation MRI monitor, expected to launch in 2028 [22] Question: Strength of disposables and services growth - Management indicated that growth in disposables is expected to align with capital sales, with potential for increased utilization with the new 3870 pump [27][28] Question: Inventory levels and backlog for the 3860 - Management confirmed they are managing inventory levels closely and are in good shape to fulfill backlog while transitioning to the 3870 [29][30] Question: Regulatory process updates for the 3870 in Europe and Japan - Management confirmed that CE mark is expected by the end of 2026, with Japan clearance anticipated by summer 2027 [33]

Core Insights - Iradimed Corporation reported record revenue and profit for Q2 2025, with revenue of $20.41 million and non-GAAP EPS of $0.49, surpassing analyst expectations and the company's own guidance [1][2][9] Financial Performance - Revenue increased by 14% year-over-year from $17.93 million in Q2 2024 to $20.41 million in Q2 2025 [2][5] - Non-GAAP EPS rose 17% from $0.42 in Q2 2024 to $0.49 in Q2 2025, while GAAP EPS increased 18% from $0.38 to $0.45 [2][6] - Gross profit margin remained stable at 78% [2][6] - Free cash flow decreased by 8% year-over-year to $4.92 million [2][6] Product Performance - MRI-compatible IV infusion pump systems, the largest product group, saw revenue growth of approximately 15.5% compared to Q2 2024 [5] - Patient vital signs monitoring systems grew by approximately 1.3%, while disposables expanded by 14% [5] - Ferro magnetic detection systems experienced the highest growth at 32% compared to Q2 2024 [5] Business Strategy - The company focuses on technological innovation, expanding its installed base, and maintaining regulatory compliance [4] - A new manufacturing facility is nearing completion to meet increasing demand [4][6] Geographic Distribution - Domestic sales accounted for 89% of total revenue, up from 86% a year ago, while international sales remained flat or lower [7] Future Outlook - For Q3 2025, revenue guidance is set between $20.5 million and $20.9 million, with projected non-GAAP EPS of $0.45 to $0.49 [11] - Fiscal 2025 revenue outlook has been raised to $80.0–$82.5 million, with non-GAAP EPS expected between $1.76 and $1.86 [11] - The next-generation MRidium 3870 pump is expected to launch commercially in late 2025 [10]

Financial Data and Key Metrics Changes - For Q1 2025, the company achieved revenue of $19.5 million, an 11% increase from $17.6 million in Q1 2024 [4][11] - Gross profit margin was reported at 76.1%, consistent with Q1 2024 [12] - GAAP diluted earnings per share increased by 16% to $0.37 from $0.32 in Q1 2024 [13] - Non-GAAP adjusted net income was $5.3 million or $0.42 per diluted share, up 17% from $4.6 million or $0.36 per diluted share in Q1 2024 [14] Business Line Data and Key Metrics Changes - Revenue from IV infusion pump systems grew 16% to $6 million, while disposable revenue increased 23% to $4.9 million [11][12] - Patient vital signs monitoring systems revenue remained steady at $6.5 million [12] - Domestic sales accounted for 82% of total revenue, up from 76% in Q1 2024, with domestic revenue increasing 19% to $16 million [12] Market Data and Key Metrics Changes - International sales declined 15% to $3.5 million [12] - Device revenue increased 9% to $13 million, driven by pump revenue and FMD systems [12] Company Strategy and Development Direction - The company is focused on increasing monitoring sales in 2025, anticipating a decline in pump revenues later in the year [21] - The new 3,870 MRIV pump is expected to be a revenue driver in 2026, with clearance anticipated in mid-2025 [9][10] - The company is nearing completion of a new facility, with full operations expected by July 2025 [10] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the impact of tariffs, noting that only 3% of revenue is connected to high tariff sources [6][7] - The FDA's responsiveness has been positive, with ongoing interactions indicating progress towards device clearance [25][27] - The company expects Q2 2025 revenue guidance of $19.7 million to $19.9 million, reiterating full-year revenue guidance of $78 million to $82 million [10] Other Important Information - Operating expenses were $9.4 million, or 48% of revenue, down from 49% in Q1 2024 [12] - Cash flow from operations was $4.3 million, up 10% from $3.9 million in Q1 2024 [14] Q&A Session Summary Question: Any anomalies in disposable revenue growth? - Management indicated that some backlog was worked down in Q1, contributing to the growth, but expects future growth to align with capital growth [17][18] Question: Confidence in monitoring sales recovery? - Management emphasized efforts to boost monitoring sales through adjusted compensation structures, with strong bookings already seen in Q2 [20][22] Question: Status of FDA interactions and clearance timeline? - Management noted ongoing interactive questions from the FDA, suggesting a positive sign, with expectations for clarity in the next three to four weeks [24][27]